Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Interruptions of antiretroviral therapy in human immunodeficiency virus infection, are they detrimental to neurocognitive functioning?

  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Fumaz, Carmina R.|||0000-0003-0838-3395
  • Prats, Anna|||0000-0002-3586-4525
  • Ferrer, Maria Jose
  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Moltó, José|||0000-0003-4564-1963
  • Gómez Melis, Guadalupe|||0000-0003-4252-4884
  • Garolera Freixa, Maite|||0000-0001-7443-8249
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
Background: Since interruptions of antiretroviral treatment may entail clinical risks for HIV-infected individuals, we investigated their impact on neurocognitive functioning. Methods: Cross-sectional study comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (non-interruption group, NIG). Interruption was defined as the discontinuation of HAART for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. Results: A total of 83 subjects participated in the study (IG: n=27, NIG: n=56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13.8; NIG, 10.2 [p=0.003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59.25%; NIG, 33.92% [p=0.02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. Conclusions: In our study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells

  • Ternette, Nicola
  • Yang, Hongbing
  • Partridge, Thomas
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Fischer, Roman
  • Charles, Philip D.
  • Dudek, Nadine L.
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Crespo Casal, Manuel|||0000-0001-9016-0515
  • Fischer, William M.
  • Korber, Bette T. M.
  • Nielsen, Morten
  • Borrow, Persephone
  • Purcell, Anthony W.
  • Brander, Christian|||0000-0002-0548-5778
  • Dorrell, Lucy
  • Kessler, Benedikt M.
  • Hanke, Tomáš|||0000-0002-6076-9546
Recognition and eradication of infected cells by cytotoxic T lymphocytes is a key defense mechanism against intracellular pathogens. High-throughput definition of HLA class I-associated immunopeptidomes by mass spectrometry is an increasingly important analytical tool to advance our understanding of the induction of T-cell responses against pathogens such as HIV-1. We utilized a liquid chromatography tandem mass spectrometry workflow including de novo-assisted database searching to define the HLA class I-associated immunopeptidome of HIV-1-infected human cells. We here report for the first time the identification of 75 HIV-1-derived peptides bound to HLA class I complexes that were purified directly from HIV-1-infected human primary CD4 + T cells and the C8166 human T-cell line. Importantly, one-third of eluted HIV-1 peptides had not been previously known to be presented by HLA class I. Over 82% of the identified sequences originated from viral protein regions for which T-cell responses have previously been reported but for which the precise HLA class I-binding sequences have not yet been defined. These results validate and expand the current knowledge of virus-specific antigenic peptide presentation during HIV-1 infection and provide novel targets for T-cell vaccine development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients, Screening DXA Scan

  • Negredo Puigmal, Eugènia|||0000-0001-5298-1734
  • Bonjoch, Anna|||0000-0002-5343-2881
  • Gómez-Mateu, Moisés
  • Estany Quera, Carla|||0000-0001-6993-5865
  • Puig, Jordi|||0000-0002-4075-0346
  • Pérez-Álvarez, Núria|||0000-0001-6582-1553
  • Rosales, Joaquin
  • Di Gregorio, Silvana
  • Del Rio, Luis|||0000-0003-0720-0673
  • Gómez Melis, Guadalupe|||0000-0003-4252-4884
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
Algorithms for bone mineral density (BMD) management in HIV-infected patients are lacking. Our objective was to assess how often a dual-energy x-ray absorptiometry (DXA) scan should be performed by assessing time of progression to osteopenia/osteoporosis. All DXA scans performed between 2000 and 2009 from HIV-infected patients with at least two DXA were included. Time to an event (osteopenia and osteoporosis) was assessed using the Kaplan-Meier method. Strata (tertiles) were defined using baseline minimum T scores. Differences between strata in time to an event were compared with the log-rank test. Of 391 patients (1,639 DXAs), 49.6% had osteopenia and 21.7% osteoporosis at their first DXA scan. Of the 112 (28.6%) with normal BMD, 35.7% progressed to osteopenia; median progression time was 6.7 years. These patients were stratified: "low-risk" (baseline minimum T score.